Effect of Tetrabenazine on Stroop Interference in HD
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effect of Tetrabenazine on Stroop Interference in Huntington Disease|
- Change in Stroop Interference Score [ Time Frame: 6 hours ] [ Designated as safety issue: No ]Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.
|Study Start Date:||March 2013|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Experimental: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
Drug: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01834911
|Contact: Robert Fekete, MDfirstname.lastname@example.org|
|Contact: Robert Fekete, MD||9143451313|
|United States, New York|
|Terence Cardinal Cooke Health Care Center||Recruiting|
|New York, New York, United States, 10029|
|Contact: Katherine Becker, LMSW 212-360-3711|
|Principal Investigator: Robert Fekete, MD|
|Sub-Investigator: Silky Singh, MD|